Tag Archives: liposarcoma

Halaven Shows Survival Advantage in Liposarcoma – FDA Approved

Halaven (eribulin mesylate) was approved by the FDA for the treatment of patients with unresectable or advanced liposarcoma. The treatment is approved for patients who previously had undergone chemotherapy with an anthracycline drug. It was previously approved for patients with breast cancer who had undergone at least two prior chemotherapeutic regimens, including an anthracycline and a taxane. Continue reading